Modulation of human monocyte/macrophage activity by tocilizumab, abatacept and etanercept: An in vitro study

European Journal of Pharmacology

Volumn 780, Issue , 2016, Pages 33-37

  Obeng, Joyce Afrakoma ^a   Amoruso, Angela ^a   Camaschella, Gian Luca Ermanno ^b   Sola, Daniele ^b   Brunelleschi, Sandra ^a   Fresu, Luigia Grazia ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b ALS Center   (Italy)

Author keywords

Biological drugs; Inflammation; Monocytes macrophages

Indexed keywords

ABATACEPT; CD163 ANTIGEN; CD206 ANTIGEN; CD36 ANTIGEN; CD86 ANTIGEN; ETANERCEPT; GELATINASE B; LYMPHOCYTE ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SUPEROXIDE; TOCILIZUMAB; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MMP 9 GENE; MONOCYTE; MONOCYTE DERIVED MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ABATACEPT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; CELL SURVIVAL; ETANERCEPT; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MONOCYTES; PHENOTYPE; PPAR GAMMA;

EID: 84966389681     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.03.028     Document Type: Article

References (20)

1. P. Chomarat, J. Banchereau, J. Davoust, and A.K. Palucka IL-6 switches the differentiation of monocytes from dendritic cells to macrophages Nat. Immunol. 1 6 2000 510 514
2. D.L. Cooper, S.G. Martin, J.I. Robinson, S.L. Mackie, C.J. Charles, J. Nam, and et al. FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy PLoS One 7 1 2012 e28918
3. N. Hogg, D.G. Palmer, and P.A. Revell Mononuclear phagocytes of normal and rheumatoid synovial membrane identified by monoclonal antibodies Immunology 56 1985 673 681
4. M.G. Ismair, C. Ries, F. Lottspeich, C. Zang, H.J. Kolb, and P.E. Petrides Autocrine regulation of matrix metalloproteinase-9 gene expression and secretion by tumor necrosis factor-alpha (TNF-alpha) in NB4 leukemic cells: specific involvement of TNF receptor type 1 Leukemia 12 1998 1136 1143
5. E.C. Keystone, M.H. Schiff, J.M. Kremer, S. Kafka, M. Lovy, T. DeVries, and D.J. Burge Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum. 50 2 2004 353 363
6. R.W. Kinne, B. Stuhlmüller, and G.R. Burmester Cells of the synovium in rheumatoid arthritis. Macrophages Arthritis Res. Ther. 9 6 2007 224
7. J.M. Kremer, M. Dougados, P. Emery, P. Durez, J. Sibilia, W. Shergy, and et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double blind, randomized, placebo-controlled trial Arthritis Rheum. 52 8 2005 2263 2271
8. L. Lavagno, G. Gunella, C. Bardelli, S. Spina, L.G. Fresu, I. Viano, and et al. Anti-inflammatory drugs and tumor necrosis factor-alpha production from monocytes: role of transcription factor NF-kappa B and implication for rheumatoid arthritis therapy Eur. J. Pharmacol. 501 1-3 2004 199 208
9. M.Y. Md Yusof, and P. Emery Targeting interleukin-6 in rheumatoid arthritis Drugs 73 4 2013 341 356
10. S. Mia, A. Warnecke, X.-M. Zhang, V. Malmström, and R.A. Harris An optimised protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-β yields a dominant immunosuppressive phenotype Scand. J. Immunol. 79 5 2014 305 314
11. K.M. Mohler, D.S. Torrance, C.A. Smith, R.G. Goodwin, K.E. Stremler, V.P. Fung, and et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists J. Immunol. 151 1993 1548 1561
12. M.A. Myers, L.C. McPhail, and R. Snyderman Redistribution of protein kinase C activity in human monocytes: correlation with activation of the respiratory burst J. Immunol. 135 1985 3411 3416
13. N. Nishimoto, K. Yoshizaki, N. Miyasaka, K. amamoto, S. Kawai, T. Takeuchi, and et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebocontrolled trial Arthritis Rheum. 50 6 2004 1761 1769
14. N. Nishimoto, K. Terao, T. Mima, H. Nakahara, N. Takagi, and T. Kakehi Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease Blood 112 10 2008 3959 3964
15. A. Palma, P.P. Sainaghi, A. Amoruso, L.G. Fresu, G. Avanzi, M. Pirisi, and et al. Peroxisome proliferator-activated receptor-gamma expression in monocytes/macrophages from rheumatoid arthritis patients: relation to disease activity and therapy efficacy - a pilot study Rheumatology (Oxford) 51 11 2012 1942 1952
16. S.C. Robinson, K.A. Scott, and F.R. Balkwill Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha Eur. J. Immunol. 32 2 2002 404 412
17. M. Rossol, S. Kraus, M. Pierer, C. Baerwald, and U. Wagner The CD14(bright) CD16+monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population Arthritis Rheum. 64 3 2012 671 677
18. A.N. Schweitzer, and A.H. Sharpe Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production J. Immunol. 161 6 1998 2762 2771
19. H. Shu, B. Wong, G. Zhou, Y. Li, J. Berger, J.W. Woods, and et al. Activation of PPAR alpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells Biochem. Biophys. Res. Commun. 267 2000 345 349
20. M.E. Weinblatt, M.H. Schiff, E.M. Ruderman, C.O. Bingham 3rd, J. Li, J. Louie, and et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study Arthritis Rheum. 58 7 2008 1921 1930